Personalis Inc. (PSNL)
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Aaron L. Tachibana - CFO & COO Christopher M.
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital William Bonello - Craig-Hallum Vidyun Bais - BTIG Daniel Brennan - Cowen Yuko Oku - Morgan Stanley Swayampakula Ramakanth - H.C. Wainwright Operator Greetings.
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.26 per share a year ago.
Hanover Insurance Set to Report Q1 Earnings: What to Expect
THG's Q1 results are likely to reflect a reduction in Personal Lines policy count in the Midwest and the implementation of deductibles in most of Personal Lines.
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.46 per share a year ago.
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exciting Technology At Personalis, But Profitability Eludes Them
Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financials with a good cash position and no debt, but struggles with test reimbursement impacting gross margins. Partnerships with Tempus AI and Merck provide capital and credibility, but profitability is projected to be years away, possibly until 2029.
Personalis (PSNL) Upgraded to Buy: Here's Why
Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Personalis price target raised to $9 from $7 at Lake Street
Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. With cash to breakeven, a strong commercial partner, "robust" clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as "another transformative year" for Personalis, the analyst tells investors.
